// App-Quantinova.ai

: Matching Adjusted Indirect Comparison to Assess the Relative Efficacy of Idelalisib in Double-Refractory Follicular Lymphoma

Researchers

Presenter

  • Nishanthan Rajakumaraswamy

Principal Investigators

  • Eleonora Lovato

  • Harry Smith

  • Timothy Bagguley

  • Alexandra Smith

  • Russell Patmore

  • Robert Marcus

Medical Centers

  • Gilead Sciences, London, United Kingdom

  • Gilead Sciences, London, GBR

  • University of York, York, United Kingdom.

  • Epidemiology and Cancer Statistics Group, University of York, York, United Kingdom

  • Hull and East Yorkshire Hospitals NHS Trust

  • HCA Haematology London, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Non-Hodgkin's Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Idelalisib

  • Rituximab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved